ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS (ANAPEM)

Double blind RCT aiming to compare the efficacy of Anakinra vs placebo, on top of the standard of care, on restoration of myocardial function at 3 days following treatment initiation, in children admitted for acute myocarditis in intensive care units.

Study Overview

• Status: Not yet recruiting
• Conditions: PEDIATRIC ACUTE MYOCARDITIS
• Intervention / Treatment: Drug: Anakinra, KINERET®

Detailed Description

Activation of the inflammasome is increasingly recognized in the pathogenesis of acute myocarditis. We hypothesize that by blocking inflammasome using anakinra, we interfere with the key mechanism driving myocardial inflammation and fibrosis, allowing for restauration of myocardial function compared to standard of care alone. Children from ≥ 3 months to < 18 years of age hospitalized in the Intensive Care Unit for acute myocarditis defined as a reduced left ventricle ejection fraction below 50% and troponin T rise (>1.5x normal range) will be randomized to either receive SC Anakinra or Placebo in addition to standard of care treatment. Primary endpoint: Proportion of children with recovered left ventricle ejection fraction (LVEF ≥ 50%) measured by echocardiography at 3 days after treatment initiation.

Secondary endpoints:

1. Proportion of children with recovered left ventricle ejection fraction (LVEF

   ≥ 50%) measured by echocardiography at 7 and 28 days after treatment initiation. Patients who die or undergo heart transplant within the first 7 and 28 days after treatment initiation respectively will be considered as a failure (i.e, LVEF < 50%). Patients who still require ECMO at 7 and 28 days after treatment initiation respectively will also be considered as failure (i.e., LVEF < 50%).

2. Time to recovery of normal left ventricular ejection fraction (LVEF ≥ 50%) within the first 3 days after treatment initiation
3. Proportion of children requiring ECMO within the first 3 days after treatment initiation
4. Proportion of children who undergo heart transplant within 6 months after treatment initiation
5. Time to all-cause death within 6 months after treatment initiation
6. Time to cardiovascular-related death within 6 months after treatment initiation
7. Proportion of children with drug-related side effects (hypersensitivity, neutropenia, drug-related liver enzymes elevation…)
8. a- NT proBNP at inclusion and at 24 hours, 48 hours, 72 hours following treatment initiation - Troponin T at inclusion and at 24 hours, 48 hours, 72 hours following treatment initiation - Proportion of children with ventricular tachycardia assessed by EKG at inclusion and at 24 hours, 48 hours, 72 hours following treatment initiation - b - NT proBNP at 7 days following treatment initiation - Troponin T at 7 days following treatment initiation - Proportion of children with ventricular tachycardia assessed by EKG at 7 days following treatment initiation - Proportion of children with fibrosis on cardiac MRI according to modified Lake Louise criteria at 6 months following treatment initiation - Proportion of children with dilated cardiomyopathy on cardiac echocardiography (Left ventricular end diastolic diameter ˃ 2 SD with altered systolic function <50%) at 3 and 6 months following treatment initiation - Proportion of children with ventricular arrhythmia at 6 months following treatment initiation.

• Study Type: Interventional
• Enrollment (Estimated): 110
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Ramy CHARBEL, Study Principal Investigator; Phone Number: 01 45 21 32 05; Email: ramy.charbel@aphp.fr

Study Locations

• France
  • France
    • Le Kremlin-Bicêtre, France, France, 94275
      • Bicêtre Hospital - APHP, Pediatric intensive care unit
      • Contact: Ramy CHARBEL, Study Principal Investigator; Phone Number: 01 45 21 32 05; Email: ramy.charbel@aphp.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Children from ≥ 3 months to < 18 years of age
• Hospitalized in the Intensive Care Unit (ICU) for acute myocarditis defined as : - a reduced left ventricle ejection fraction below 50% and - troponin T rise (>1.5x normal range), Signed informed consent by legal representative and patient according to the legislation.

Exclusion Criteria:

• Children weighing less than 5 Kgs
• Known anterior cardiomyopathy or operated cardiopathy
• Neutropenia (< 1,5 × 10^9 /L).
• Known hypersensitivity to Anakinra or any of its excipients (citric acid anhydrous, sodium chloride, disodium EDTA dihydrate, polysorbate 80, E. coli derived proteins)
• Administration of a live vaccine in the 4 weeks prior to inclusion
• Hepatitis B infection, defined as positive HBsAg and/or detectable HBV DNA (PCR). Patients with increased risk of Tuberculosis (TB) infection

• Recent tuberculosis infection or with active TB

  • Close contact with a patient with TB
  • Patients recently arrived less than 3 months from a country with high prevalence of TB
  • A chest radiograph suggestive of TB
• Patients with overt concomitant bacterial infection
• Patients previously treated with another biotherapy
• Patients with any type of immunodeficiency or cancer
• Anti TNF-α within the past 14 days
• Malignancy or history of malignancy or any comorbidity limiting survival or conditions predicting inability to complete the study Ongoing or recent use of any other medication Known inhibitors/inducers of cytochrome P450
• Pregnancy or breastfeeding
• No affiliation to the Social Security
• Current enrollment in another clinical trial
• Inability of the legal representative (and the patient, when applicable) to understand the national language (French)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Anakinra; Anakinra, KINERET, solution for injection in pre-filled syringe. Posology for clinical trial: 4 mg/Kg (maximum 100 mg) once daily subcutaneously for 7 days.	Drug: Anakinra, KINERET®; Patients will be randomized to receive Anakinra 4mg/Kg (maximum 100 mg) subcutaneously once a day for 7 days
Placebo Comparator: Placebo; Placebo of Anakinra, solution of NaCl 0.9% Posology for clinical trial: 4 mg/Kg (maximum 100 mg) once daily subcutaneously for 7 days.	Drug: Anakinra, KINERET®; Patients will be randomized to receive Anakinra 4mg/Kg (maximum 100 mg) subcutaneously once a day for 7 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of children with recovered left ventricle ejection fraction ≥ 50% measured by echocardiography at 3 days after treatment initiation.	Main objective: To compare the efficacy of Anakinra vs placebo, on top of the standard of care, on restoration of myocardial function at 3 days following treatment initiation, in children admitted for acute myocarditis in intensive care units. Primary endpoint: Proportion of children with recovered left ventricle ejection fraction (LVEF ≥ 50%) measured by echocardiography at 3 days after treatment initiation. Patients who die within the first 3 days after treatment initiation or patients who still require ECMO at 3 days after treatment initiation will be considered as a failure.	3 days

Secondary Outcome Measures

Outcome Measure	Time Frame
Proportion of children with recovered left ventricle ejection fraction ≥ 50% measured by echocardiography at 7 and 28 days after treatment initiation. Patients who die or undergo heart transplant within the first 7 and 28 days after treatment initiation	7 and 28 days
Time to recovery of normal left ventricular ejection fraction (LVEF ≥ 50%) within the first 3 days after treatment initiation	3 days
Proportion of children requiring ECMO within the first 3 days after treatment initiation	3 days
Proportion of children who undergo heart transplant within 6 months after treatment initiation	6 months
Time to all-cause death within 6 months after treatment initiation	6 months
Time to cardiovascular-related death within 6 months after treatment initiation	6 months
Proportion of children with drug-related side effects (hypersensitivity, neutropenia, drug-related liver enzymes elevation…)	6 months
following treatment initiation-TroponinT at inclusion and at24 hours,48 hours,72 hours following treatment initiation-Proportion of children with ventricular tachycardia assessed by EKG at inclusion and at 24hours,48hours,72hours following treatment init	24,48,72 hours
NTproBNP at7days, Troponin T at7days,Proportion of children with ventricular tachycardia assessed by EKG at7days, Proportion of children with fibros on cardiac MRI at6months,Proportion of children with dilated cardiomyopathy,with ventricular arrhythmia	7 days - 3 and 6 months

Collaborators and Investigators

• Sponsor: Assistance Publique - Hôpitaux de Paris

Study record dates

Study Major Dates

• Study Start (Estimated): February 1, 2026
• Primary Completion (Estimated): December 1, 2029
• Study Completion (Estimated): December 1, 2029

Study Registration Dates

• First Submitted: January 19, 2026
• First Submitted That Met QC Criteria: January 19, 2026
• First Posted (Actual): January 28, 2026

Study Record Updates

• Last Update Posted (Actual): January 28, 2026
• Last Update Submitted That Met QC Criteria: January 19, 2026
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Keywords: Inflammation; Pediatric; Anti-IL1; Anakinra; Myocarditis
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Cardiomyopathies; Pathological Conditions, Signs and Symptoms; Myocarditis; Inflammation; Peptides; Amino Acids, Peptides, and Proteins; Proteins; Biological Factors; Intercellular Signaling Peptides and Proteins; Cytokines; Interleukin 1 Receptor Antagonist Protein
• Other Study ID Numbers: APHP230825; 2025-521478-32-00 (Ctis)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No